Zelira Therapeutics and Levin Health talk upcoming chronic pain clinical trial
Zelira Therapeutics Ltd s (ASX:ZLD) (OTCMKTS:ZLDAF) Dr Oludare Odumosu and Levin Health Limited s Mark Brayshaw discuss plans for its upcoming chronic pain clinical trial. Levin will use Zelira s ZTL-106 formulation for testing on retired athletes in a chronic pain treatment study at La Trobe University in Melbourne. The trial will be sponsored by Levin, which will pay Zelira to design and manage the study, while both companies will share any commercialisation profits.
Quick facts: Zelira Therapeutics Ltd
Follow
Zelira Therapeutics well positioned for multiple product launches in 2021
Zelira Therapeutics Ltd s (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) Harry Karelis and Dr Oludare Odumosu speak to Proactive s Andrew Scott soon after announcing record product sales and licensing revenues of A$225,000 during the March quarter - up 249% on the prior six months. They say the revenue growth demonstrates the start of the company’s commercialisation ramp-up, with growth driven largely by the successful December 2020 launch of the Sprinjene CBD oral care product in the USA.
Quick facts: Zelira Therapeutics Ltd
Price: 0.06 AUD